The 2001-2003 Alaska HIV Prevention Plan describes the HIV epidemic in Alaska, provides information on populations at increased risk of infection, and recommends strategies to prevent further spread of HIV in Alaska. The HIV Prevention Plan also serves to guide uses of HIV prevention funds from the Centers forDisease Control and Prevention (CDC) within our state. This plan differs from previous plans developed by the Alaska HIV Prevention Planning Group in that it is more geographically specific, it strongly emphasizes populations at high risk, and it recommends specific interventions to reduce the spread of HIV/AIDS in Alaska.
The 2004-2006 Alaska HIV Prevention Plan is the fifth comprehensive plan produced by the Alaska HPPG. It describes the epidemiology of HIV/AIDS in Alaska and related risk factors, the populations at greatest need for HIV prevention interventions, and recommendations for interventions that are most appropriate to meet these needs. The Plan is designed to provide guidance for HIV prevention activities in all sectors and areas of Alaska for the next three years. It is intended to guide specific interventions for those at greatest risk of HIV infection; to generate community discussion and input; to encourage collaboration among individuals, organizations, and community groups providing HIV prevention and care; and to encourage integration of HIV prevention interventions into services for people likely to engage in risk behaviors -- all with the goal of preventing HIV and AIDS in Alaska.
The comparative evaluation of effectiveness of different nontreponema tests in analysis of cerebrospinal fluid. The liquor from 100 patients with syphilis was analyzed using Bordet-Gengou test, VDRL test and micro-precipitation reaction with cardiolipin antigen. The Bordet-Gengou test and VDRL test made in Russia or abroad are equally effective in analysis of positive samples of liquor and twice surpass the same capacity of micro-precipitation reaction with cardiolipin antigen in case of neurosyphilis with symptoms and thrice surpass in case of asymptomatic neurosyphilis. VDRL test is a simple standardized nontreponema reaction which can substitute labor-consuming non-unified liquorologic complex in laboratory diagnostic of neurosyphilis. The testing of liquor on the basis of micro-precipitation reaction with cardiolipin antigen is non-effective and results in false negative results in Bordet-Gengou and VDRL positive tests determining high risk of erroneous clinical considerations.
Carl Peter Thunberg, a Swedish medical doctor and botanist who visited Japan in 1775 as a medical doctor attached to the Dutch Trade House in Dejima, Nagasaki, taught the treatment of syphilis using mercury water to Japanese doctors and interpreters. This therapy is based on the oral administration of a 0.014% solution of mercuric chloride and was published in 1754 by Gerard van Swieten in Vienna, who questioned the utility of the conventional salivation therapy. The dose was set taking safety into account. Kogyu Yoshio, a Japanese-Dutch interpreter, had already read about it in a book written by J. J. Plenck, when he was taught about the therapy by Thunberg. He recorded Thunberg's teachings in his book "Komohijiki", presenting details of various formulations, including a high-dose formulation. The mercury therapy was subsequently spread across the country by medical doctors who learned Western medicine through the Dutch. In the 1820's, Genshin Udagawa, who read a number of Western medical books, published books on Western drugs. In these books, G. Udagawa included precise information on "Swieten Yakushu-hu (medicated alcohol)", including information on the dosage, formulation, mode of usage, and precautions for use. The maximum dose of mercuric chloride established chloride established by van Swieten was included in the Japanese Pharmacopoeia up to its 5th edition.